Chemed Corp (NYSE:CHE) director George J. Walsh III has sold a portion of his holdings in the company, according to the latest SEC filings. The transaction, which took place on September 26, involved the sale of 400 shares at a price of $597.47 each, totaling nearly $239,000.
The sale reduced Walsh's direct ownership in the company to 3,046 shares. Additionally, the reporting documents indicated an indirect ownership of 434 shares held by Walsh's spouse. This move comes amidst Chemed Corp's ongoing business activities in the home health care services sector.
Chemed Corp, with a history that includes a former name of Roto-Rooter Inc., has been a player in the services industry, specifically focusing on home health care services. The company's stock, traded under the ticker CHE, is watched by investors who are interested in the healthcare service industry's performance.
The SEC filing did not disclose any specific reason for the sale, but such transactions are common among corporate insiders and can be influenced by a variety of factors, including personal financial planning, diversification of assets, or other strategic considerations.
Investors and market watchers often pay close attention to insider transactions as they may provide insights into executives' perspectives on the company's future performance. However, it's important to note that insider sales and purchases can be motivated by many different personal factors and not necessarily reflect on the company's outlook.
Chemed Corp's latest stock transactions by its director are now a matter of public record, providing transparency to the market and ensuring that investors have access to the same information as insiders.
In other recent news, Chemed Corporation announced significant developments. The company declared a 25% increase in its quarterly cash dividend, raising the payout to 50 cents per share. This decision continues Chemed's history of consistent shareholder returns, marking 213 consecutive quarters of dividend issuance throughout its 53-year existence.
In its Q2 2024 earnings call, Chemed reported mixed results. VITAS Healthcare, a subsidiary, demonstrated robust growth with increases in admissions and average daily census. The acquisition of Covenant Health positively impacted VITAS's financials, potentially adding between $30 million to $32 million to its annual revenue. However, Roto-Rooter, another subsidiary, experienced a downturn in revenue and call volume.
Chemed revised its 2024 earnings per share guidance to $23.55 to $23.80, reflecting these recent developments. Despite Roto-Rooter's current revenue decline, the company maintains a positive outlook for its long-term growth potential. These updates underscore Chemed's commitment to its investors and its strategic approach to managing its diverse portfolio.
InvestingPro Insights
To provide additional context to Director George J. Walsh III's recent sale of Chemed Corp (NYSE:CHE) shares, let's examine some key financial metrics and insights from InvestingPro.
Chemed Corp's market capitalization stands at $9.05 billion, reflecting its significant presence in the home health care services sector. The company's revenue growth of 7.6% in the most recent quarter demonstrates continued expansion in its core business areas.
InvestingPro Tips highlight Chemed's strong dividend history, having raised its dividend for 15 consecutive years and maintained payments for an impressive 54 years. This consistent dividend policy aligns with the company's stable financial position and may appeal to income-focused investors despite Director Walsh's recent share sale.
The company's profitability is underscored by its healthy gross profit margin of 35.96% and operating income margin of 15.68% over the last twelve months. These figures suggest that Chemed maintains efficient operations in its service-oriented business model.
While the stock trades at a relatively high P/E ratio of 30.36, InvestingPro Tips indicate that it's trading at a low P/E ratio relative to near-term earnings growth, with a PEG ratio of 0.95. This could suggest that the stock may still offer value despite its current valuation multiples.
Investors should note that Chemed's stock has shown a 17% price total return over the past year, outperforming many of its peers. The company's next earnings date is set for October 29, 2024, which may provide further insights into its financial performance and strategic direction.
For those interested in a deeper analysis, InvestingPro offers 11 additional tips for Chemed Corp, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.